Skip to main content
Vistin Pharma logo

Vistin Pharma — Investor Relations & Filings

Ticker · VISTN ISIN · NO0010734122 LEI · 5967007LIEEXZXFQY092 OL Manufacturing
Open in API
Filings indexed 519 across all filing types
Latest filing 2025-04-25 Report Publication Anno…
Country NO Norway
Listing OL VISTN

About Vistin Pharma

https://www.vistin.com/

Vistin Pharma is a pharmaceutical company specializing in the production of Metformin Hydrochloride, an Active Pharmaceutical Ingredient (API). The company operates as a pure-play, global supplier, providing high-quality Metformin to pharmaceutical companies worldwide. In addition to the standard API, Vistin Pharma offers specialized grades such as Direct Compressible (DC) Metformin. With over 50 years of experience, the company emphasizes sustainable manufacturing from its dedicated European production facility.

Recent filings

Filing Released Lang Actions
2024 Annual Report Vistin Pharma ASA
Report Publication Announcement Classification · 100% confidence The document is a short announcement (772 characters) stating that the 2024 Annual Report is attached and available on the company website. Per the 'Menu vs Meal' rule, an announcement stating a report is attached or available is classified as a Report Publication Announcement (RPA), not the report itself. FY 2024
2025-04-25 English
Vistin Pharma ASA: First quarter 2025 financial results
Earnings Release Classification · 99% confidence The document is titled 'Quarterly result' and explicitly states 'First quarter report for 2025'. It details financial performance (Revenue, EBITDA, Cash flow, Balance sheet) for the period ending March 2025, following IFRS and IAS 34 for interim financial reporting. This content structure and period specificity strongly indicate a comprehensive quarterly financial report, which aligns with the definition of an Interim / Quarterly Report (IR). Although it mentions a proposed dividend for the AGM, the primary focus and bulk of the text is the detailed financial review for Q1 2025. Q1 2025
2025-04-25 English
Vistin Pharma ASA: First quarter 2025 financial results
Investor Presentation Classification · 98% confidence The document is structured as a presentation, indicated by the repeated 'Agenda' slides and the presence of CEO/CFO names and a date (25 April 2025). It contains detailed financial highlights for Q1 2025 (revenue, EBITDA, balance sheet tables) and discusses market outlook and strategy. Crucially, it mentions: 'The Board of Directors has proposed for the Annual General Meeting an ordinary cash dividend of total NOK 1.25 per share, to be paid in June' and lists the 'Top 20 shareholders as of end March 2025'. This content strongly suggests it is an Investor Presentation (IP) used to communicate quarterly results and strategic updates to investors, often preceding or accompanying an earnings release or AGM notice. Since it is a comprehensive presentation detailing financial results, it fits the Investor Presentation (IP) category better than a simple Earnings Release (ER) or a formal Annual Report (10-K).
2025-04-25 English
Vistin Pharma ASA: First quarter 2025 financial results
Earnings Release Classification · 100% confidence The document explicitly announces the 'First quarter 2025 financial results' and provides key financial highlights (Revenue, EBITDA, Net Profit) for Q1 2025. This strongly indicates an Earnings Release (ER). Furthermore, the document mentions that the 'Q1 report and presentation' are enclosed and that a conference call will be held today, which is typical for an ER announcement. Since the text provides the summary highlights rather than being the full, detailed report, ER is the most appropriate classification over IR (Interim Report). The document length (3307 chars) is short, and it announces the availability of the full report, but the primary content is the results summary, making ER more specific than RPA or RNS. Q1 2025
2025-04-25 English
Vistin Pharma ASA: Invitation to Q1 2025 conference call
Report Publication Announcement Classification · 99% confidence The document is titled "Vistin Pharma ASA: Invitation to Q1 2025 conference call" and explicitly states that the company "will host a conference call for all shareholders and interested parties at the same day at 08:30 CET" following the release of Q1 results. It provides webcast and telephone registration links for this event. This is an announcement about an upcoming event (a conference call) where results will be discussed, not the full results release (ER) or the transcript of the call itself (CT). Since the primary purpose is to invite participants to a scheduled call, it most closely aligns with the function of a Call Transcript (CT) announcement or a general Regulatory Filing (RNS). Given the specific nature of announcing a conference call that will include a Q&A session (which implies a transcript will follow), and the fact that it is an invitation rather than the actual results or the transcript, it fits best as an announcement related to a call. However, none of the definitions perfectly capture an 'Invitation to a Conference Call'. The closest related categories are CT (Call Transcript) or ER (Earnings Release). Since it is an invitation to the event where the results will be discussed, and it precedes the actual discussion, it is often categorized as a precursor to the CT or ER. Given the options, and recognizing that the event described is a conference call, classifying it as a Call Transcript (CT) announcement precursor is plausible, but the 'Menu vs Meal' rule suggests that if it's an announcement about a future event, it might be RNS. Since the event is a conference call, and CT is the closest functional match for the content being discussed, I will check if it fits RPA. RPA is for announcing the *publication* of a report. This announces a *call*. Therefore, RNS (Regulatory Filings) is the most appropriate fallback for an announcement that doesn't fit the specific event types like ER or CT, or the RPA definition.
2025-04-15 English
Vistin Pharma ASA: Fourth quarter and preliminary 2024 financial results
Earnings Release Classification · 99% confidence The document is titled "VISTIN PHARMA ASA – FOURTH QUARTER AND PRELIMINARY 2024 FINACIAL RESULTS" and contains detailed financial figures for Q4 2024 and the full year 2024, including Revenue, EBITDA, Balance Sheet details, and Cash Flow analysis. It explicitly states that the financial report follows IFRS and IAS 34 for interim financial reporting, and that the figures are unaudited. This structure—a comprehensive report covering a period shorter than a full year (Q4) and presenting preliminary full-year results—is characteristic of an Interim/Quarterly Report (IR). It is not just an Earnings Release (ER) because it includes extensive balance sheet and cash flow details, nor is it the full Annual Report (10-K). It is a detailed financial report for a specific period. Q4 2024
2025-02-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.